Research on repurposing statins, beta-blockers and G-CSF as disease-modifying agents to decompensated cirrhosis

Updated guidelines on non-invasive tests for liver disease assessment

A phase 2a, randomized, double-blind, placebo-controlled study: GSK3228836 treatment leads to HBsAG decline and induction of interferon gamma related proteins and chemokines

Results of CHECKMATE 040 COHORT 5: Long-term efficacy, safety and biomarker analysis of nivolumab

Potential clinical benefits of ATEZO plus BEV in HCC patients with prior LRTS: update of the IMBrave150